A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication

Leukemia
Steven J KussickB L Wood

Abstract

In a 5-year survey of nonpromyelocytic/nonmonocytic acute myeloid leukemias (AMLs) diagnosed in the University of Washington Hematopathology Laboratory, we identified 19 cases containing distinctive, cup-like nuclear indentation in 10% or more of the blasts ('AML-cuplike'). Fourteen of these cases (74%) demonstrated near-complete loss of HLA-DR expression, while the other five cases showed partial loss of HLA-DR. A total of 16 of the cases (84%) demonstrated internal tandem duplication (ITD) of the Flt3 gene. When compared to a selected set of AMLs lacking this nuclear morphology, AML-cuplike was significantly more likely to lack HLA-DR and CD34 expression, to express CD123 without CD133, to have a normal karyotype, and to harbor the Flt3 ITD. To characterize AML-cuplike in an unselected series of AMLs, we analyzed 42 consecutive nonpromyelocytic/nonmonocytic AMLs diagnosed in our laboratory during a 6-month period in 2002. Strikingly, in this unselected series, there was a statistically significant coincidence of invaginated nuclear morphology, loss of HLA-DR, and presence of the Flt3 ITD beyond that expected if these three features were unrelated, suggesting that AMLs with these three features may represent a distinct AML sub...Continue Reading

References

Oct 30, 1971·Lancet·M Seabright
Jan 1, 1996·Rapid Communications in Mass Spectrometry : RCM·M G Qian, D M Lubman
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Apr 12, 2003·Leukemia·M WetzlerM R Baer
Aug 30, 2003·Archives of Pathology & Laboratory Medicine·Steven J Kussick, Brent L Wood
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Feb 27, 2004·British Journal of Haematology·Derek L StirewaltJerald P Radich

❮ Previous
Next ❯

Citations

Nov 27, 2008·International Journal of Hematology·Tohru InabaNaohisa Fujita
Jun 18, 2009·International Journal of Hematology·Masahiro ManabeKensuke Ohta
Jan 17, 2008·Blood·Fiona E Craig, Kenneth A Foon
May 8, 2007·International Journal of Hematology·Akira Okano, Tohru Inaba
Oct 5, 2014·Journal of Hematology & Oncology·Sanam LoghaviJoseph D Khoury
Sep 22, 2010·American Journal of Clinical Pathology·John M BennettW Richard Burack
Mar 5, 2016·Surgical Pathology Clinics·Valentina Nardi, Robert P Hasserjian
Oct 30, 2015·Laboratory Medicine·Erica Robinson, Carleen Van Siclen
Jul 7, 2009·Hematology/oncology Clinics of North America·Amy Heerema-McKenney, Daniel A Arber
Dec 17, 2015·Asia-Pacific Journal of Clinical Oncology·Pulkit RastogiSubhash Varma
Jan 24, 2015·American Journal of Hematology·Edgar JostRoland Fuchs
Jan 9, 2008·Leukemia Research·Meilani SyampurnawatiYoshitake Hayashi
Apr 18, 2013·International Journal of Laboratory Hematology·R P Hasserjian
Nov 6, 2014·Hematological Oncology·Aroonima MisraAnita Chopra
Jun 11, 2014·European Journal of Haematology·Shano NaseemNeelam Varma
Oct 22, 2013·European Journal of Haematology·Paola CarluccioGiorgina Specchia
Oct 24, 2006·Leukemia Research·Meilani SyampurnawatiYoshitake Hayashi
Jul 23, 2015·Applied Immunohistochemistry & Molecular Morphology : AIMM·Pulkit RastogiSubhash Varma
Dec 21, 2007·The Korean journal of laboratory medicine·Heewon MoonWha Soon Chung
Dec 3, 2015·PloS One·Marco Antonio Escárcega-TameDoris Cerecedo
Mar 10, 2016·Journal of Clinical Medicine·Jennifer N Saultz, Ramiro Garzon
Feb 13, 2018·Journal of Pediatric Hematology/oncology·Özlem TüfekçiŞebnem Yilmaz
May 10, 2018·International Journal of Laboratory Hematology·A MerinoA Ermens
Feb 26, 2019·Cytometry. Part B, Clinical Cytometry·Xueyan ChenSindhu Cherian
Feb 9, 2011·Pediatric Hematology and Oncology·Chihiro KawakamiHiroshi Tamai
Jun 13, 2017·The Journal of Clinical Investigation·Catherine Matte-MartoneWarren D Shlomchik
Aug 24, 2012·Applied Immunohistochemistry & Molecular Morphology : AIMM·Marian Rollins-RavalChristine G Roth
Mar 26, 2021·Best Practice & Research. Clinical Haematology·Robert P Hasserjian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.